Background: Natalizumab is the first monoclonal antibody therapy approved for multiple sclerosis (MS). Its therapeutic mechanism is the blockade of the α4-integrin subunit of the adhesion molecule (AM) very late activation antigen-4 (VLA-4), which leads to an inhibition of immune cell extravasation into the central nervous system (CNS).
Methods: We investigated changes in the expression levels of unblocked α4-integrin and further AM (intercellular adhesion molecule-1, -2, -3 (cICAM-1, -2, -3), leukocyte function associated antigen-1 (LFA-1)) on peripheral blood mononuclear cells (PBMC) determined by flow cytometry from 25 patients with MS before the first natalizumab infusion and before the fourth infusion. In 15 MS patients AM expression was evaluated every 3 months over 1 year.
Results:We found a significant decrease (p < 0.0001) of unblocked α4-integrin cell surface expression on all investigated PBMC subsets (T cells −61.7%, B cells −69.1%, monocytes/macrophages −46.4%) in the blood of MS patients after 3 months of natalizumab treatment. Moreover, a continuous decrease (p < 0.05) of unblocked α4-integrin expression levels was seen after 3, 6, 9, and 12 months. As a secondary effect, expression levels of the other investigated AM were differentially affected.
Conclusions:Results show a sustained decrease of unblocked α4-integrin expression not only in all patients but also in all investigated PBMC subsets. This probably results in a continuously decreasing transmigration of PBMC into the CNS and may explain the improved clinical efficacy in the second treatment year and also the increasing risk of progressive multifocal leukoencephalopathy during long-term natalizumab therapy. We conclude that AM expression profiles are promising candidates for the development of a biomarker system to determine both natalizumab treatment response and patients at risk for opportunistic CNS infections.
LassmannHBruckWLucchinettiC. The immunopathology of multiple sclerosis: an overview. Brain Pathol2007; 17: 210–218.
2.
KermodeAGThompsonAJToftsPMacManusDGKendallBEKingsleyDP. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain1990; 113: 1477–1489.
3.
KrausJOschmannP. The impact of interferon-beta treatment on the blood-brain barrier. Drug Discov Today2006; 11: 755–762.
4.
CannellaBRaineCS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol1995; 37: 424–435.
5.
SpringerTA. Adhesion receptors of the immune system. Nature1990; 346: 425–434.
6.
PilzGWipflerPLadurnerGKrausJ. Modern multiple sclerosis treatment – what is approved, what is on the horizon. Drug Discov Today2008; 13: 1013–1025.
7.
EngelhardtB. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines. J Neurol Sci2008; 274: 23–26.
8.
YednockTACannonCFritzLCSanchez-MadridFSteinmanLKarinN. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature1992; 356: 63–66.
ArchelosJJPrevitaliSCHartungHP. The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci1999; 22: 30–38.
11.
ButcherEC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell1991; 67: 1033–1036.
12.
FawcettJHolnessCLNeedhamLATurleyHGatterKCMasonDY. Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature1992; 360: 481–484.
13.
BoLPetersonJWMorkSHoffmanPAGallatinWMRansohoffRM. Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. J Neuropathol Exp Neurol1996; 55: 1060–1072.
14.
de FougerollesARStackerSASchwartingRSpringerTA. Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1. J Exp Med1991; 174: 253–267.
15.
KrausJEngelhardtBChatzimanolisNBauerRTofighiJKuehneBS. Cell surface bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity. J Neuroimmunol2002; 122: 175–185.
16.
NiinoMBodnerCSimardMLAlatabSGanoDKimHJ. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol2006; 59: 748–754.
17.
PolmanCHReingoldSCEdanGFilippiMHartungHPKapposL. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol2005; 58: 840–846.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983; 33: 1444–1452.
20.
KrausJEngelhardtBKühneBSLaskeCStolzETraupeH. Soluble and cell surface bound adhesion molecules in blood and cerebrospinal fluid as diagnostic markers and parameters for disease activity, disease severity and treatment efficacy in patients with multiple sclerosis. J Med Lab2001; 25: 548–556.
21.
PolmanCHO’ConnorPWHavrdovaEHutchinsonMKapposLMillerDH. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
22.
DuggerKJZinnKRWeaverCBullardDCBarnumSR. Effector and suppressor roles for LFA-1 during the development of experimental autoimmune encephalomyelitis. J Neuroimmunol2009; 206: 22–27.
23.
KleineTOBenesL. Immune surveillance of the human central nervous system (CNS): different migration pathways of immune cells through the blood–brain barrier and blood–cerebrospinal fluid barrier in healthy persons. Cytometry A2006; 69: 147–151.
24.
KrausJBauerRChatzimanolisNEngelhardtBTofighiJBregenzerT. Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis. J Neurol2004; 251: 464–472.
25.
BullardDCHuXSchoebTRCollinsRGBeaudetALBarnumSR. Intercellular adhesion molecule-1 expression is required on multiple cell types for the development of experimental autoimmune encephalomyelitis. J Immunol2007; 178: 851–857.
26.
KrausJOschmannPEngelhardtBStolzEKuehneBSLaskeC. CD45RA+ ICAM-3+ lymphocytes in cerebrospinal fluid and blood as markers of disease activity in patients with multiple sclerosis. Acta Neurol Scand2000; 102: 326–332.
